MXCT · Maxcyte, Inc.
Market Cap
$127.98M
Shares
103.21M
MXCT metrics
64 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$1.24
Market cap
$127.98M
Price action
19 metricsPrice change (1W)
-8.1%
Price change (30D)
+15.9%
Price change (3M)
+0.8%
Price change (6M)
+63.2%
Price change (YTD)
-20.0%
Price change (1Y)
-10.8%
Trailing year
Price change (5Y)
-92.1%
52-week high
$1.83
52-week low
$0.68
Change from 52-week high
-32.2%
Change from 52-week low
+83.4%
Annualized volatility
69.7%
Beta
1.7
RSI (14D)
48.2
Price vs SMA 50
+0.4%
Price vs SMA 200
+10.0%
Avg volume (3M)
1.09M
Relative volume
0.6
Average dollar volume
$1.36M
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
103.21M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.1×
reciprocal yield 24.3%
P / book
0.8
reciprocal yield 124.0%
FCF yield
-18.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-27.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-12
Profitability
9 metricsGross margin
79.2%
Operating margin
-134.6%
Trailing 12 months
Net margin
-114.8%
Gross profit (TTM)
$24.60M
Operating profit (TTM)
−$41.79M
Net income (TTM)
−$35.64M
Trailing 12 months
Diluted EPS (TTM)
$-0.32
FCF margin
-76.1%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-14.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$31.05M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.4%
Year over year · more shares
Revenue CAGR (3Y)
-9.3%
Revenue CAGR (5Y)
+4.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-22.4%
Return on assets
-19.3%
Debt / equity
—
Current ratio
12.3
EBITDA (TTM)
−$37.63M
Free cash flow (TTM)
−$23.64M
Quick ratio
11.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$105.69M
Latest balance sheet
Cash & equivalents
$15.04M
Total assets
$184.67M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$22.98M
Capital expenditures (TTM)
$665,000
R&D (TTM)
$16.76M
SG&A (TTM)
—
Stock compensation (TTM)
$4.96M
R&D / revenue
54.0%
Stock compensation / revenue
16.0%
Ownership (13F)
3 metrics13F filers
123
13F filer change QoQ
-8
Institutional ownership
61.4%
Short interest
3 metricsShort interest
1.2%
Latest settlement · 1.1 days to cover
Days to cover
1.1d
Short-squeeze score
47 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—